Cargando…

Combination immunotherapy: a road map

Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent years. However, despite the remarkable clinical efficacy of these agents in a number of malign...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ott, Patrick A., Hodi, F. Stephen, Kaufman, Howard L., Wigginton, Jon M., Wolchok, Jedd D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319100/ https://www.ncbi.nlm.nih.gov/pubmed/28239469 http://dx.doi.org/10.1186/s40425-017-0218-5

Ejemplares similares

Improved Endpoints for Cancer Immunotherapy Trials
por: Hoos, Axel, et al.
Publicado: (2010)

The future of cancer immunotherapy: microenvironment-targeting combinations
por: Murciano-Goroff, Yonina R., et al.
Publicado: (2020)

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Hiding the road signs that lead to tumor immunity
por: Schaer, David A., et al.
Publicado: (2011)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014)

The delicate balance of melanoma immunotherapy
por: Gyorki, David E, et al.
Publicado: (2013)

Two roads for oncolytic immunotherapy development
por: Kaufman, Howard L., et al.
Publicado: (2019)

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Cancer immunotherapy trials: leading a paradigm shift in drug development
por: Emens, Leisha A., et al.
Publicado: (2016)

Opportunistic infections in patients treated with immunotherapy for cancer
por: Kyi, Chrisann, et al.
Publicado: (2014)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
por: Yuan, Jianda, et al.
Publicado: (2013)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
por: Hodi, F. Stephen, et al.
Publicado: (2021)

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31(st) anniversary annual meeting
por: Kaufman, Howard L., et al.
Publicado: (2017)

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
por: Ott, Patrick A., et al.
Publicado: (2015)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
por: Holmgaard, Rikke B., et al.
Publicado: (2016)

Acquired resistance to immunotherapy in MMR-D pancreatic cancer
por: Hu, Zishuo Ian, et al.
Publicado: (2018)

Shared cancer neoantigens: Making private matters public
por: Klebanoff, Christopher A., et al.
Publicado: (2018)

The many faces of the anti-COVID immune response
por: Vardhana, Santosha A., et al.
Publicado: (2020)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

Refusing to TAP out: 16 new human TEIPPs identified
por: Gigoux, Mathieu, et al.
Publicado: (2018)

Mapping genetic interactions in cancer: a road to rational combination therapies
por: Tutuncuoglu, Beril, et al.
Publicado: (2019)

A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations
por: Brown, Sarah R., et al.
Publicado: (2022)

New Roads Open Up for Implementing Immunotherapy in Mesothelioma
por: Cornelissen, R., et al.
Publicado: (2012)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

A Road Map for the Global Elimination of Congenital Syphilis
por: Kamb, Mary L., et al.
Publicado: (2010)

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients
por: Page, David B, et al.
Publicado: (2015)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Road map for the clinical application of the basophil activation test in food allergy
por: Santos, A. F., et al.
Publicado: (2017)

T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road
por: Crowther, Michael D., et al.
Publicado: (2020)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013)

Repair road map
por: LeBrasseur, Nicole
Publicado: (2006)

Road maps to the future
por: Hawrylyshyn, Bohdan
Publicado: (1980)

Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment
por: Aris, Mariana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t5vqnl6pajhe75dh69qgpe4q3d